{
    "nctId": "NCT03719326",
    "briefTitle": "A Study to Evaluate Safety/Tolerability of Immunotherapy Combinations in Participants With Triple-Negative Breast Cancer or Gynecologic Malignancies",
    "officialTitle": "A Phase 1/1b Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Breast or Gynecologic Malignancies",
    "overallStatus": "COMPLETED",
    "conditions": "TNBC - Triple-Negative Breast Cancer, Ovarian Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1",
    "allocation": "NON_RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 35,
    "primaryOutcomeMeasure": "Incidence of Adverse Events (AEs)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Female participants, 18 years or older\n* Measurable disease per radiographic evaluation\n* Performance status 0 or 1\n* Available archival tissue sample (within 2 years) or a fresh tumor biopsy may be required\n* Adequate organ, cardiac, and bone marrow function\n* Dose escalation\n\n  * Participants with breast cancer:\n\n    * Locally advanced or metastatic triple negative breast cancer (ER-negative, PgR-negative, and HER2-negative according to ASCO/CAP guidelines) with disease progression\n    * No available alternative or curative therapy\n    * Participants may have received any number of prior therapies for advanced/recurrent and progressive disease\n  * Participants with ovarian cancer:\n\n    * Locally advanced or metastatic ovarian cancer with disease progression\n    * No available alternative or curative therapy\n    * Participants may have received any number of prior therapies for advanced/recurrent and progressive disease\n* Dose expansion\n\n  * Participants with breast cancer:\n\n    * Locally advanced or metastatic triple negative breast cancer (ER-negative, PgR-negative, and HER2-negative according to ASCO/CAP guidelines)\n    * Disease progression after no more than 3 prior lines of therapy\n  * Participants with ovarian cancer:\n\n    * Locally advanced or metastatic ovarian cancer that is platinum-resistant\n    * Disease progression after no more than 3 prior lines of therapy\n\nExclusion Criteria:\n\n* Received a live, attenuated vaccine within 4 weeks prior to first study treatment\n* Prior anticancer treatment including approved agents, systemic radiotherapy, or investigational therapy within 4 weeks prior first study treatment\n* Cancer other than the disease under study within 2 years prior to study entry, except for some cancers with a low risk of spreading like non-melanoma skin cancers\n* Inability to swallow oral medications\n* Participant is breastfeeding, pregnant, or expects to become pregnant during the study\n* Active autoimmune disease or documented history of autoimmune disease within 2 years prior to first study treatment\n* History of peptic ulcer or stomach bleeding within 6 months prior to first study treatment\n* Use of drugs contraindicated by the protocol within 4 weeks prior to and during study treatment\n* Prior treatment with drugs that suppress the immune system within 2 weeks prior to first study treatment\n* Presence of metastases in the brain or cancer spreading into the cerebrospinal fluid - CSF (leptomeningeal disease)\n* HIV, Hepatitis B, and C test results negative prior to first study treatment\n* Major surgery within 4 weeks prior to first study treatment\n* Participants who have previously received maximum cumulative lifetime anthracycline dosage or baseline ejection fraction \\<50% (on heart echography)",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}